Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The impact of TP53 mutations in patients with myelofibrosis undergoing SCT

Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, highlights the results of the first study that provides evidence on TP53 mutations for transplant and non-transplant settings in myelofibrosis (MF). He underscores that genotype and phenotype did not play a role in patients with or without TP53 mutations, but in TP53-mutated patients post-transplant acute myeloid leukemia (AML) was more frequent. In addition, allele frequency played an important role in overall survival (OS) and relapse-free survival (RFS). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.